JHJunya Hasegawa

Junya Hasegawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junya Hasegawa has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Mochihito Suzuki

    Department of Orthopedic Surgery and Rheumatology Nagoya University Graduate School of Medicine Nagoya Japan

    5 shared publications
  • Kenya Terabe

    Department of Orthopedic Surgery and Rheumatology Nagoya University Graduate School of Medicine Nagoya Japan

    3 shared publications
  • Ryo Sato

    Department of Orthopedic Surgery and Rheumatology Nagoya University Graduate School of Medicine Aichi Japan

    3 shared publications
  • Shiro Imagama

    Department of Orthopedic Surgery and Rheumatology Nagoya University Graduate School of Medicine Aichi Japan

    3 shared publications
  • Shuji Asai

    Department of Orthopedic Surgery and Rheumatology Nagoya University Graduate School of Medicine Nagoya Japan

    3 shared publications
  • Takaya Sugiura

    Department of Orthopedic Surgery and Rheumatology Nagoya University Graduate School of Medicine Aichi Japan

    3 shared publications

Latest Publications

  • Risk of Pneumocystis Pneumonia in Patients With Rheumatoid Arthritis and the Role of Prophylactic Salazosulfapyridine

    by Ryo Sato, Kenya Terabe, Takahiro Imaizumi, Koji Sakamoto, Kikue Sato, Junya Hasegawa, Takaya Sugiura, Yusuke Ono, Mochihito Suzuki, Shuji Asai, et al.

    Objectives: This study aimed to assess the risk factors for Pneumocystis pneumonia (PCP) in patients with rheumatoid arthritis (RA) and investigate the potential of salazosulfapyridine (SASP) as a prophylactic agent. Methods: The present study analyzed data from the Japanese Diagnosis Procedure Combination database, which provides comprehensive inpatient data (including diagnoses, procedures, and medications) covering a large portion of the population. We identified patients with RA who developed PCP among 14 190 patients diagnosed with RA at admission with a treatment history. Patients with RA who were receiving therapeutic doses of drugs for PCP were defined as having PCP. A nested case–control analysis was performed to compare patients with RA and PCP with age‐ and sex‐matched control patients with RA without PCP in a ratio of 1:20. Results: The cohort comprised 132 patients with PCP and 2575 controls. The risk factors for PCP in RA were chronic obstructive pulmonary disease, methotrexate (MTX), biological/targeted synthetic DMARDs (b/tsDMARDs), and high‐dose glucocorticoids. SASP may have a protective effect against PCP, particularly in patients with RA treated with MTX and/or b/tsDMARDs. Conclusion: The large sample size of the present study suggests that SASP may be associated with a reduced PCP risk in RA patients.


  • Evaluation of Vertebrae in Patients With Ankylosing Spondylitis Using Hounsfield Unit Values

    by Junya Hasegawa, Mochihito Suzuki, Kenji Kishimoto, Ryo Sato, Yusuke Ohno, Takaya Sugiura, Hiroto Yamamoto, Kenya Terabe, Shuji Asai, Shiro Imagama

    Objective: To evaluate vertebral Hounsfield Unit (HU) values on computed tomography (CT) in patients with ankylosing spondylitis (AS) compared to patients without AS and to examine differences in HU values between ankylosed and nonankylosed vertebrae in patients with AS. Methods: This cross‐sectional study included 34 patients with AS and 73 patients without AS who underwent spinal CT between 2004 and 2022. HU values were measured from C3 to L5 in patients with AS and from L1 to L5 in patients without AS. Propensity score (PS) matching based on age and sex was performed to compare HU values between groups. Additionally, HU values were compared between ankylosed and nonankylosed vertebrae within the AS group. Results: After PS matching, vertebral HU values were significantly lower in patients with AS than in patients without AS (136.4 vs. 197.1, p = 0.009). Among patients with AS, HU values were highest in the cervical spine, followed by the thoracic and lumbar regions. Ankylosed vertebrae showed significantly lower HU values than nonankylosed vertebrae across all spinal levels ( p < 0.001). Conclusion: Vertebral HU values were lower in patients with AS compared to age‐ and sex‐matched patients without AS. HU values were highest in the cervical spine, and ankylosed vertebrae consistently exhibited lower HU values than nonankylosed vertebrae across all spinal regions.


  • Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis

    by Hironobu Kosugiyama, Shuji Asai, Kenya Terabe, Tomonori Kobayakawa, Yutaka Yoshioka, Tatsuo Watanabe, Toshihisa Kojima, Yasumori Sobue, Takefumi Kato, Takayoshi Fujibayashi, et al.

    Aim: To compare the clinical effectiveness of baricitinib and filgotinib in the treatment of rheumatoid arthritis (RA).Methods: This retrospective study included 101 and 103 consecutive patients treated with baricitinib and filgotinib, respectively, between 2020 and 2023. Drug retention was analyzed using Kaplan–Meier curves, with the log‐rank test for between‐group comparisons. Differences in Clinical Disease Activity Index (CDAI) score from baseline were assessed using paired t‐tests, and generalized estimating equations were used to compare the treatment groups.Results: Baseline characteristics were similar between the baricitinib and filgotinib groups. Drug retention rates due to ineffectiveness or adverse events did not differ significantly between the two groups. In the baricitinib group, the estimated mean CDAI score significantly decreased from 17.8 at baseline to 9.1 at 4 weeks, 6.6 at 12 weeks, and 6.3 at 24 weeks (p < 0.001 for all comparisons). In the filgotinib group, the estimated mean CDAI score significantly decreased from 16.5 at baseline to 7.8 at 4 weeks, 6.2 at 12 weeks, and 6.1 at 24 weeks (p < 0.001 for all comparisons). No significant differences were observed between the two groups in CDAI score at any time point evaluated, or in the proportion of patients who achieved CDAI remission (CDAI ≤ 2.8) at baseline (7% vs. 5%) and after 4 (23% vs. 21%), 12 (33% vs. 33%), and 24 weeks (33% vs. 37%).Conclusion: Baricitinib and filgotinib demonstrated comparable drug retention rates and effectiveness in reducing disease activity among patients with RA over a 24‐week follow‐up period.

  • Open Access

    Association between frailty and oral function in rheumatoid arthritis patients: A multi-center, observational study

    by Yasumori Sobue, Mochihito Suzuki, Yoshifumi Ohashi, Ryo Sato, Yusuke Ohno, Junya Hasegawa, Takaya Sugiura, Kenya Terabe, Shuji Asai, Shiro Imagama

    Objectives: This study aims to investigate the association between frailty and oral function in rheumatoid arthritis (RA) patients and to identify practical markers for early frailty detection and potential intervention strategies. Patients and methods: A multi-center observational cohort study (T-FLAG) included a total of 661 RA patients (186 males, 475 females; mean age: 68.5±13.5 years; range, 18 to 100 years) between June 2023 and August 2023. Frailty was assessed using the Kihon Checklist (KCL) (frailty: score ≥8). Oral function scores were based on Question 13 (“difficulty eating hard foods”), Question 14 (“choking”), and Question 15 (“dry mouth”) of the KCL. Receiver operating characteristic (ROC) curves were generated to assess the association between frailty and oral function scores. Multivariate logistic regression was used to analyze factors associated with oral function. Results: Among the 661 participants, 39.5% were frail. Frailty rates tended to increase with increasing oral function scores. The optimal cut-off score for oral function corresponding to frailty was 2 points, with a specificity of 89.2% and a sensitivity of 54.8%. Multivariate analysis identified age and Health Assessment Questionnaire-Disability Index (HAQ-DI) as significant factors associated with oral function decline (i.e., a total score of ≥2 for Questions 13-15 of the KCL). Conclusion: Frailty is strongly associated with oral function decline in RA patients. This finding highlights the importance of monitoring the oral function of RA patients, since it not only reflects physical function, but also serves as a potential marker of frailty. Targeted interventions to improve oral function may play a vital role in reducing frailty risk and enhancing the overall well-being of RA patients.


  • Association between sarcopenia and locomotive syndrome in rheumatoid arthritis patients: A multicenter observational study (T‐FLAG)

    by Yasumori Sobue, Mochihito Suzuki, Yoshifumi Ohashi, Ryo Sato, Hironobu Kosugiyama, Yusuke Ohno, Junya Hasegawa, Takaya Sugiura, Kenya Terabe, Shuji Asai, et al.